Streetbeat News

Products Services

SYTA

Siyata Mobile Inc. has expanded its partnership with Hyperion Partners, a leading T-Mobile dealer, to include the distribution of Siyata's SD7 Push-to-Talk over Cellular handsets and accessories. This expansion aims to accelerate global order intake and drive growth by leveraging Hyperion's extensive reach. The SD7 handsets are already being used by Hyperion's customers in government and commercial sectors through T-Mobile Direct Connect.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 1:19 pm

SCPX

NightHawk Biosciences has officially changed its name to Scorpius Holdings, Inc. and will trade under the new ticker 'SCPX' starting February 6, 2024. This change reflects the company's transition to a specialized contract development and manufacturing organization (CDMO) focusing on large molecule biomanufacturing. The company's share structure and shareholder rights remain unaffected. CEO Jeff Wolf highlighted the strategic move to address the biopharmaceutical sector's demand for clinical-scale biologic manufacturing, noting positive feedback and an enhanced sales pipeline.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 1:18 pm

INKT

MiNK Therapeutics, Inc. (NASDAQ:INKT) announced the publication of promising results from a phase 1/2 study of agenT-797 in treating moderate-to-severe ARDS secondary to SARS-CoV-2, published in Nature Communications. The study showed significant promise in improving survival rates and reducing secondary infections with a favorable safety profile. The company plans to further advance agenT-797 in patients with viral ARDS through a large platform trial.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 1:17 pm

CSCO

NVDA

Nvidia Corp has partnered with Cisco Systems Inc to develop corporate AI computing infrastructures, aiming to broaden AI technology accessibility. This collaboration allows Cisco to integrate Nvidia's AI technology into its networking solutions, enhancing Nvidia's distribution channels and enabling Cisco to capitalize on the AI investment surge. The partnership was announced at Cisco Live in Amsterdam, indicating a strategic move to decentralize AI hardware deployment beyond major data-center operators like Microsoft Corp, Amazon.Com Inc, Alphabet Inc's Google, and Meta Platforms Inc.

Portfolio Pulse from Anusuya Lahiri

February 06, 2024 | 1:16 pm

RARE

Ultragenyx Pharmaceutical Inc. announced positive data from its Transpher A study on UX111 (ABO-102) AAV gene therapy for treating Sanfilippo syndrome type A (MPS IIIA). The study showed rapid and sustained decreases in heparan sulfate levels in patients, correlating with improved cognitive development. Results will be presented at the WORLDSymposium 2024.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 1:16 pm

SRRK

Scholar Rock (NASDAQ:SRRK) announced new preclinical data for SRK-439, showing potential benefits for healthy weight loss by preserving lean mass and improving fat mass loss. The data, presented at the Keystone Symposia, demonstrated SRK-439's effectiveness in combination with GLP-1 receptor agonists in diet-induced obesity mice. SRK-439, a novel myostatin inhibitor, also showed incremental lowering of fasting glucose levels. Scholar Rock plans to initiate a proof-of-concept study with apitegromab in obesity, with trial initiation expected in mid-2024.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 1:15 pm

UNH

UnitedHealthcare has initiated a program in collaboration with Audubon Area Community Care Clinic and Girls Inc. to educate individuals about Type 2 Diabetes, implement preventive measures, and improve disease management. This initiative is part of UnitedHealthcare's broader efforts to address chronic health conditions and improve public health outcomes.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 1:15 pm

RVPH

Reviva Pharmaceuticals Holdings, Inc. (RVPH) announced a KOL event on February 15, 2024, to discuss Phase 3 RECOVER trial results of brilaroxazine for schizophrenia. The event will feature experts Larry Ereshefsky and Mark Opler, focusing on the unmet medical need in schizophrenia treatment and brilaroxazine's potential. The trial showed positive outcomes, meeting all primary and secondary endpoints with a well-tolerated side effect profile. Brilaroxazine is also being developed for other neuropsychiatric and inflammatory diseases, having received Orphan Drug Designation for PAH and IPF.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 1:13 pm

TWST

Twist Bioscience and Element Biosciences have announced a collaboration to launch 'Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow', which is expected to be available soon. This collaboration aims to enhance genomic research and diagnostics capabilities.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 1:13 pm

ECOR

electroCore, Inc. (NASDAQ:ECOR), a bioelectronic medicine company, announced the issuance of U.S. Patent No. 11,894,148 for treating disorders associated with the Coronaviridae family (COVID) using electrical impulses. The patent covers methods of reducing C-reactive protein levels in the blood by applying electrical impulses to the vagus nerve.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 1:11 pm